Company
Cresilon
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
3
510(k), De Novo and PMA
Device trials
0
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
Recall records
0
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$158M
8 Form D offerings, 2017 to 2026
Equity
$112M
Stock sold for cash
Debt and convertible notes
$29.0M
$29.0M of it convertible
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: convertible note, $29.0M raised of $29.0M sought, first sale Apr 24, 2026, 217 investors. $17.2M was in other or unstated securities.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Apr 24, 2026 | Convertible note | $29.0M | $29.0M | 217 | Rule 506(c)Agent: Paulson Investment Company, LLCCommissions $3.4M | Form D/A ↗Jun 26, 20261 amendment |
| Nov 21, 2025 | Equity | $6.7M | $6.7M | 55 | Rule 506(c)Agent: Paulson Investment Company, LLCCommissions $869K | Form D ↗Dec 8, 2025 |
| Apr 11, 2025 | Options or warrants | $17.2M | $34.8M | 95 | Rule 506(b)Agent: Paulson Investment Company, LLCCommissions $2.2M | Form D ↗Sep 5, 2025 |
| Apr 18, 2024 | Equity | $25.0M | $25.0M | 237 | Rule 506(c)Agent: Paulson Investment Company, LLCCommissions $3.1M | Form D ↗Jan 31, 2025 |
| Aug 3, 2023 | Equity | $17.2M | $38.0M | 309 | Rule 506(b)Agent: Paulson Investment Company, LLCCommissions $2.2M | Form D ↗Oct 8, 2024 |
| Dec 17, 2021 | Equity | $25.0M | $25.0M | 308 | Rule 506(c)Agent: Paulson Investment Company, LLCCommissions $3.2M | Form D ↗Oct 18, 2022 |
| Jan 29, 2021 | Equity | $24.5M | $45.3M | 170 | Rule 506(b)Agent: Paulson Investment Company, LLCCommissions $2.8M | Form D ↗Feb 16, 2021 |
| Dec 29, 2017 | Equity | $13.3M | $19.3M | 55 | Rule 506(b) | Form D ↗Jan 12, 2018 |
Company details
From the company's latest Form D.
- Legal name
- Cresilon, Inc.
- Headquarters
- Brooklyn, New York
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Biotechnology
- SEC filer
- CIK 1728054 ↗
Executives, directors and promoters
As listed on the latest Form D.
- Joseph LandolinaExecutive Officer, Director
- Isaac MillerDirector
- Scott LevineExecutive Officer
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Cresilon.
Latest FDA decisions
K253609 · Decided Dec 12, 2025 · 24 days after receipt
Device type: Hemostatic Wound Dressing Without Thrombin Or Other Biologics (QSY) · General & Plastic Surgery
- TRAUMAGEL®510(k)
K240713 · Decided Aug 14, 2024 · 152 days after receipt
Device type: Hemostatic Wound Dressing Without Thrombin Or Other Biologics (QSY) · General & Plastic Surgery
K213652 · Decided Jun 28, 2023 · 586 days after receipt
Device type: Hemostatic Wound Dressing Without Thrombin Or Other Biologics (QSY) · General & Plastic Surgery
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
No device trials list this company as lead sponsor.
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.